FDA approves Lutathera® for pediatric patients with gastroenteropancreatic neuroendocrine tumors
“Lutathera is now the very first therapy approved specifically for children with GEP-NETs, offering new hope to young patients living with this rare cancer,” said Tina Deignan, Therapeutic Area Head, Oncology US. “Radioligand therapies have extraordinary potential to shape the future of cancer care. With this approval, we have taken another vital step toward fulfilling that vision, strengthening our commitment to researching and developing the RLT platform across multiple cancer types and treatment settings.”
Share:
More News
“Phanes is very excited about partnering with Roche on this novel approach to treat patients with SCLC, LCNEC and EP-NECs,” said Rita Laeufle, MD, PhD, Chief Medical Officer (CMO) of Phanes. “DLL3 is highly expressed in SCLC, LCNEC and EP-NECs and an important target for treating these cancers. We believe
“Through our clinical development program, we continue to ask the tough questions in an effort to fully explore the potential of novel coformulations and combinations that build on the foundation of KEYTRUDA, with a goal to improve upon current standards of care and help even more patients with cancer,” said
“The VERSATILE-002 trial is evaluating Versamune® HPV + KEYTRUDA® (pembrolizumab) in patients with HPV16-positive HNSCC. Median overall survival (“mOS”) is 30 months (n=53) in first line recurrent metastatic HNSCC; Published results for immune checkpoint inhibitors are 7-18 months. The immune checkpoint inhibitor (ICI) naïve cohort (n=53) met its primary endpoint
“Mabwell (688062.SH) announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA), for the treatment of esophageal cancer. 9MW2821 was previously given Fast Track Designation (FTD) by the FDA for the treatment of advanced, recurrent,
